Clinical Trials
8
Active:0
Completed:4
Trial Phases
3 Phases
Phase 2:3
Phase 3:4
Phase 4:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
Phase 3
4 (50.0%)Phase 2
3 (37.5%)Phase 4
1 (12.5%)A Study to Evaluate the Effect of BioK+ 50B® on Glycemic Control in a Type 2 Diabetes Population
Phase 2
- Conditions
- Type2 Diabetes
- First Posted Date
- 2017-08-04
- Last Posted Date
- 2019-01-22
- Lead Sponsor
- Bio-K Plus International Inc.
- Target Recruit Count
- 130
- Registration Number
- NCT03239366
- Locations
- 🇨🇦
Montreal Heart Institute, Montréal, Quebec, Canada
Study of Bio-K+® in the Reduction of the Risk of Clostridium Difficile Infection and Antibiotic Associated Diarrhea
Phase 4
Terminated
- Conditions
- Clostridium Difficile InfectionAntibiotic Associated Diarrhea
- First Posted Date
- 2013-10-31
- Last Posted Date
- 2022-07-22
- Lead Sponsor
- Bio-K Plus International Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT01972932
- Locations
- 🇨🇦
Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada
Effect of BIO-K+ on Symptoms of Irritable Bowel Syndrome
Phase 2
Completed
- Conditions
- Irritable Bowel Syndrome
- First Posted Date
- 2012-03-06
- Last Posted Date
- 2017-07-31
- Lead Sponsor
- Bio-K Plus International Inc.
- Target Recruit Count
- 117
- Registration Number
- NCT01545037
- Locations
- 🇺🇸
Digestive and Liver Disease Specialists A Medical Group. Inc, Garden Grove, California, United States
🇺🇸Sprim ALS, San Francisco, California, United States
🇺🇸Westlake Medical Research, Westlake Village, California, United States
BIO-K+ CL1285 for Prevention of Recurrent Clostridium Difficile Infection
Phase 3
Suspended
- Conditions
- Recurrent Clostridium Difficile Infection
- First Posted Date
- 2010-09-16
- Last Posted Date
- 2016-01-15
- Lead Sponsor
- Bio-K Plus International Inc.
- Target Recruit Count
- 140
- Registration Number
- NCT01202630
- Locations
- 🇺🇸
Parker Jewish Institute, New Hyde Park, New York, United States
Efficacy and Safety Study in the Prevention of Antibiotic-Associated Diarrhea (AAD) and Clostridium Difficile-Associated Diarrhea (CDAD) in Hospitalized Adult Patients Exposed to Nosocomial Infection
Phase 3
Completed
- Conditions
- Antibiotic-Associated DiarrheaClostridium Difficile-Associated Diarrhea
- First Posted Date
- 2009-08-13
- Last Posted Date
- 2012-03-13
- Lead Sponsor
- Bio-K Plus International Inc.
- Target Recruit Count
- 255
- Registration Number
- NCT00958308
- Prev
- 1
- 2
- Next
News
No news found